Seneca Therapeutics, Inc. Announces Novel SVV-001 Patient Screening Test For Patient Selection With SVV-001 Therapy

Seneca Therapeutics, Inc. Announces Novel SVV-001 Patient Screening Test For Patient Selection With SVV-001 Therapy




Seneca Therapeutics, Inc. Announces Novel SVV-001 Patient Screening Test For Patient Selection With SVV-001 Therapy

PHILADELPHIA–(BUSINESS WIRE)–#SenecaValleyVirusScreeningAssay–Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics for cancer based on Seneca Valley Virus (SVV-001), announced today the successful development of a novel SVV-001 Patient Screening Test. The test uses a unique set of genes to predict sensitivity to SVV-001 in tumor cells obtained from patient samples. The SVV-001 Patient Screening Test can be used on Formalin-Fixed-Paraffin-Embedded (FFPE) tumor blocks allowing for patient screening using previous biopsies. The SVV-001 Patient Screening Test will identify which cancer patients will benefit from SVV-001 treatment either as monotherapy or in combination with other immune therapies like checkpoint inhibitors. The SVV-001 Patient Screening Test can also be used to identify types of cancer patients that will benefit from SVV-001. The test can be used to screen patients for products in the SVV-001 based Armed Construct Cancer Gene Therapy Portfolio currently in development. The selection of patients using the SVV-001 Patient Screening Test will be applicable whether the patient is treated with either the Intra-tumoral or Intravenous route of administration. The SVV-001 Patient Screening Test will be available through CLIA laboratories.

“Using the SVV-001 Patient Screening Test to select patients, it will be possible to identify and select cancer patients that will benefit from SVV-001 therapy either as monotherapy, combination therapy with check point inhibitors or therapy using SVV-001 Armed Constructs,” said Dr. Paul Hallenbeck, CSO, President and Founder of Seneca Therapeutics. “We are excited that this pre-screening test offers the ability to selectively identify which patients will likely benefit from SVV-001.”

Seneca Therapeutics is also using the SVV-001 Patient Screening Test to identify relevant cancer patient populations that could benefit from SVV-001 therapy. The company recently screened nearly 300 sarcoma samples and determined that more than 94% were sensitive to SVV-001 therapy. The work to screen other cancers for SVV-001 sensitivity is ongoing.

About Seneca Therapeutics

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 and related products. Seneca Therapeutics is also developing armed versions of SVV-001 that will selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

Contacts

Paul Hallenbeck

phallenbeck@senecatherapeutics.com

James Hussey

jhussey@senecatherapeutics.com

www.senecatherapeutics.com